ILU Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables (razor-and-blades)Illumina’s consumables-dependent business model creates durable recurring revenue once instruments are installed. Installed-base pull-through gives predictable long-term demand, supports high gross margins, and ties customer lifetime value to ongoing reagent consumption and service contracts.
Strong Cash GenerationConsistently high OCF and FCF provide lasting financial flexibility: they fund R&D, capex for instrument development, share repurchases and strategic M&A without heavy reliance on external financing, helping sustain innovation and operational execution through multi-year product cycles.
NovaSeq X Placements & Installed BaseElevated NovaSeq X placements expand a high-throughput installed base that should drive multi-year consumables pull-through and higher throughput share. A larger X base supports predictable revenue growth, shifts mix toward clinical volumes, and underpins management’s path to sustained high-single-digit growth.
Bears Say
Moderate LeverageRelative leverage is elevated for a business with cyclical end markets; nearly 1.0x debt-to-equity limits balance sheet flexibility during revenue downturns, increases interest exposure, and narrows room for aggressive buybacks or large acquisitive moves without restoring higher cash buffers.
Research Consumables WeaknessSustained weakness in research consumables reflects structural funding and demand uncertainty in academic and applied markets. Because research historically underpins long-term instrument adoption and volume growth, prolonged declines reduce top-line breadth and make consumables growth more dependent on clinical adoption.
Multi-year Earnings And Cash VolatilityPast large swings—from losses to rebound—and recent negative FCF growth momentum signal operational cyclicality and risks in sustaining margins. This variability complicates forecasting, increases reliance on execution from new products, and raises the chance that short-term shocks impair capital allocation plans.
Illumina News
ILU FAQ
What was Illumina’s price range in the past 12 months?
Currently, no data Available
What is Illumina’s market cap?
Illumina’s market cap is CHF23.69B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 76 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported CHF1.063 earnings per share for the quarter, beating the consensus estimate of CHF0.995 by CHF0.068.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.1.
How many shares outstanding does Illumina have?
Currently, no data Available
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of CHF1.063 in its last earnings report, beating expectations of CHF0.995. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in CH:ILU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF155.86 (― Upside)
CHF155.86 (― Upside)
Blogger Sentiment
Bullish
CH:ILU Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF239.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILU Company Deck
ILU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all CH:ILU earnings summariesILU Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
